留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

地诺前列酮栓与双球囊导管用于足月妊娠期高血压疾病患者引产的临床研究

刘闯,  杜建敏,  秦鸽,  罗晓华,  韩宁

刘闯, 杜建敏, 秦鸽, 罗晓华, 韩宁. 地诺前列酮栓与双球囊导管用于足月妊娠期高血压疾病患者引产的临床研究[J]. 中华全科医学, 2026, 24(5): 735-738. doi: 10.16766/j.cnki.issn.1674-4152.004479
引用本文: 刘闯, 杜建敏, 秦鸽, 罗晓华, 韩宁. 地诺前列酮栓与双球囊导管用于足月妊娠期高血压疾病患者引产的临床研究[J]. 中华全科医学, 2026, 24(5): 735-738. doi: 10.16766/j.cnki.issn.1674-4152.004479
LIU Chuang, DU Jianmin, QIN Ge, LUO Xiaohua, HAN Ning. A randomized controlled trial of dinoprostone vaginal suppository versus double-balloon catheter for labor induction in term pregnancies with hypertension[J]. Chinese Journal of General Practice, 2026, 24(5): 735-738. doi: 10.16766/j.cnki.issn.1674-4152.004479
Citation: LIU Chuang, DU Jianmin, QIN Ge, LUO Xiaohua, HAN Ning. A randomized controlled trial of dinoprostone vaginal suppository versus double-balloon catheter for labor induction in term pregnancies with hypertension[J]. Chinese Journal of General Practice, 2026, 24(5): 735-738. doi: 10.16766/j.cnki.issn.1674-4152.004479

地诺前列酮栓与双球囊导管用于足月妊娠期高血压疾病患者引产的临床研究

doi: 10.16766/j.cnki.issn.1674-4152.004479
基金项目: 

河南省医学科技攻关计划项目 SBGJ202302083

详细信息
    通讯作者:

    韩宁,E-mail: 15515609988@163.com

  • 中图分类号: R714.246

A randomized controlled trial of dinoprostone vaginal suppository versus double-balloon catheter for labor induction in term pregnancies with hypertension

  • 摘要:   目的  比较地诺前列酮阴道栓剂与双球囊导管在足月妊娠期高血压疾病患者引产中的安全性和有效性,为临床引产方法选择提供依据。  方法  选取2022年8月—2024年6月郑州大学第三附属医院收治的确诊妊娠期高血压或非重度子痫前期140例足月妊娠孕妇为研究对象,采用随机数字表法将患者分为地诺前列酮栓组(70例)与双球囊导管组(70例)。  结果  地诺前列酮栓组的24 h内阴道分娩率显著高于双球囊导管组[37例(52.86%) vs. 16例(22.86%),P<0.001],且48 h内阴道分娩率也更高[54例(77.14%) vs. 31例(44.29%),P<0.001]。地诺前列酮栓组的引产至产程开始的间隔时间[9.00(3.59, 14.25)h vs. 17.67(15.67, 19.50)h,P<0.001]和分娩间隔时间[21.85(13.02, 31.92)h vs. 27.65(24.99, 32.18)h,P=0.020]均显著短于导管组。2组总体不良反应发生率比较差异无统计学意义[16例(22.86%) vs. 11例(15.71%),P=0.284],但地诺前列酮栓组的子宫过度刺激发生率更高[6例(8.57%)vs. 0例,P=0.028]。  结论  在合并高血压疾病的足月妊娠患者引产中,地诺前列酮阴道栓剂可显著提高阴道分娩率、缩短引产所需时间,且未增加总体不良反应发生率,表明地诺前列酮阴道栓剂可作为足月妊娠期高血压疾病孕妇的优选引产方案。

     

  • 表  1  2组患者基线特征比较

    Table  1.   Comparison of baseline characteristics between the two groups of patients

    项目 双球囊导管组
    (n=70)
    地诺前列酮栓组
    (n=70)
    统计量 P值
    年龄(x±s,岁) 30.51±4.12 30.87±3.73 0.538a 0.592
    孕周[M(P25,P75), 周] 39.28(38.54,40.29) 40.00(38.64,40.33) -1.339b 0.180
    产次类型[例(%)] 0.560c 0.454
      初产妇 48(68.57) 52(74.29)
      经产妇 22(31.43) 18(25.71)
    Bishop评分[例(%)] 0.099c 0.753
      0~2分 5(7.14) 6(8.57)
      3~5分 65(92.86) 64(91.43)
    引产前血压(x±s,mmHg)
      收缩压 135.77±14.04 135.77±12.34 <0.001a 0.999
      舒张压 86.56±10.30 86.11±9.76 0.261a 0.794
    尿蛋白[例(%)] 1.458c 0.227
      阴性 51(72.86) 57(81.43)
      阳性 19(27.14) 13(18.57)
    降压治疗[例(%)] 41(58.57) 34(48.57) 1.407c 0.236
    BMI(x±s) 25.57±4.62 25.18±4.41 0.522a 0.602
    注:a为t值,b为Z值,c为χ2值。1 mmHg=0.133 kPa。
    下载: 导出CSV

    表  2  2组患者引产成功率、时间及不良反应比较

    Table  2.   Comparison of the success rate of induced abortion, time and adverse reactions between the two groups of patients

    项目 双球囊导管组
    (n=70)
    地诺前列酮栓组
    (n=70)
    统计量 P值
    24 h阴道分娩[例(%)] 16(22.86) 37(52.86) 13.390a <0.001
    48 h阴道分娩[例(%)] 31(44.29) 54(77.14) 15.842a <0.001
    引产至分娩间隔时间[M(P25, P75),h] 27.65(24.99, 32.18) 21.85(13.02, 31.92) -2.319b 0.020
    引产至产程发动间隔时间[M(P25, P75),h] 17.67(15.67, 19.50) 9.00(3.59, 14.25) -3.549b <0.001
    母婴不良反应[例(%)] 11(15.71) 16(22.86) 0.201a 0.284
    子宫过度刺激[例(%)] 0 6(8.57) 0.028c
    胎心异常[例(%)] 3(4.29) 1(1.43) 0.620c
    严重高血压[例(%)] 3(4.29) 1(1.43) 0.620c
    产后出血[例(%)] 1(1.43) 3(4.29) 0.620c
    羊水污染[例(%)] 4(5.71) 2(2.86) 0.681c
    胎盘早剥[例(%)] 0 2(2.86) 0.496c
    新生儿窒息[例(%)] 0 1(1.43) 0.999c
    中转剖宫产[例(%)] 1(1.43) 0 0.999c
    器械助产[例(%)] 1(1.43) 2(2.86) 0.999c
    产时出血[M(P25, P75),mL] 210.00(170.00,260.00) 200.00(167.50,232.50) -0.818b 0.414
    注:a为χ2值,b为Z值,c为采用Fisher精确检验。
    下载: 导出CSV
  • [1] LI F, QIN J B, ZHANG Y, et al. Prevalence of hypertensive disorders in pregnancy in China: a systematic review and meta-analysis[J]. Pregnancy Hypertens, 2021, 24: 13-21. doi: 10.1016/j.preghy.2021.02.001
    [2] VESNA D, GAROVIC R, JOHNSON J, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association[J]. Hypertension, 2022, 79(2): e21-e41.
    [3] SHANMUGALINGAM R, MAKRIS A. A summary of the 2023 Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) hypertension in pregnancy guideline[J]. Med J Aust, 2025, 222(3): 158-159.
    [4] 汪文昕, 汪若兰, 方媛媛, 等. 妊娠期高血压疾病单胎妊娠并发胎盘早剥的风险预测[J]. 中华全科医学, 2024, 22(8): 1367-1370. doi: 10.16766/j.cnki.issn.1674-4152.003638

    WANG W X, WANG R L, FANG Y Y, et al. Risk prediction of placental abruption in singleton pregnancy with hypertensive disorders of pregnancy[J]. Chinese Journal of General Practice, 2024, 22(8): 1367-1370. doi: 10.16766/j.cnki.issn.1674-4152.003638
    [5] ALLARD M, MARTIN S, DUVAL C, et al. Prévention de la prééclampsie et de ses complications[J]. Rev Med Liege, 2024, 79(5-6): 448-454.
    [6] MAGEE L A, BROWN M A, PATERSON J, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice[J]. Pregnancy Hypertens, 2022, 27: 148-169. doi: 10.1016/j.preghy.2021.09.008
    [7] TSAKIRIDIS I, MAMOPOULOS A, KARAVASILIS N, et al. Gestational hypertension and preeclampsia: an overview of national and international guidelines[J]. Obstet Gynecol Surv, 2021, 76(10): 613-633. doi: 10.1097/OGX.0000000000000942
    [8] 中华医学会妇产科学分会产科学组. 妊娠晚期促子宫颈成熟与引产指南(2024)[J]. 中华妇产科杂志, 2024, 59(11): 819-828.

    Obstetrics Group, Obstetrics and Gynecology Branch of Chinese Medical Association. Guideline of cervical ripening and labor induction during the third trimester pregnancy (2024)[J]. Chinese Journal of Obstetrics and Gynecology, 2024, 59(11): 819-828.
    [9] National Institute for Health and Care Excellence. Inducing labour[M]. London: National Institute for Health and Care Excellence, 2021: 1-45.
    [10] 方艳, 王群华, 陈红波. 妊娠期高血压疾病的早期预测模型构建[J]. 现代妇产科进展, 2024, 33(7): 506-511.

    FANG Y, WANG Q H, LI J, et al. Construction of early prediction model for hypertensive disorders in pregnancy[J]. Progress in Obstetrics and Gynecology, 2024, 33(7): 506-511.
    [11] 陈鸳鸳, 马建婷. 人口学、血常规及血清生化指标预测妊娠期高血压疾病的价值分析[J]. 中华全科医学, 2025, 23(3): 430-433.

    CHEN Y Y, MA J T, ZHANG M. The value of demography, blood routine and serum biochemical indexes in predicting hypertensive disorder complicating pregnancy[J]. Chinese Journal of General Practice, 2025, 23(3): 430-433.
    [12] 张莉莉, 关丫丫, 张林波. 血清同型半胱氨酸、中性粒细胞明胶酶相关脂质运载蛋白联合尿微量白蛋白对妊娠期高血压疾病患者早期肾损伤的诊断价值[J]. 新乡医学院学报, 2022, 39(2): 177-181.

    ZHANG L L, GUAN Y Y, WANG J. Diagnostic value of serum homocysteine, neutrophil gelatinase-associated lipid carrier protein and urinary microalbumin for early renal injury of patients with hypertensive disease of pregnancy[J]. Journal of Xinxiang Medical University, 2022, 39(2): 177-181.
    [13] PIEUX A, DE L F, MOREAU M, et al. Uterine hyperstimulation in cervical ripening with oral misoprostol versus dinoprostone vaginal pessary: a real-life single-center descriptive study[J]. J Gynecol Obstet Hum Reprod, 2025, 54(5): 102944. DOI: 10.1016/j.jogoh.2024.102944.
    [14] COLVIN Z, FENG M, WANG Y, et al. Duration of labor induction in nulliparous women with hypertensive disorders of pregnancy and maternal and neonatal outcomes[J]. J Matern Fetal Neonatal Med, 2022, 35(20): 3964-3971. doi: 10.1080/14767058.2020.1844658
    [15] CARVALHO-AFONSO M, POLICIANO C, CLODE N, et al. Cervical ripening with Foley catheter balloon: a prospective cohort of 320 women[J]. Int J Gynaecol Obstet, 2025, 170: 768-773. doi: 10.1002/ijgo.70088
    [16] LI S Y, HE H, ZHAO J, et al. Comparison of outcomes of labor induction with dinoprostone vaginal insert (PROPESS) and double balloon cook catheter in term nulliparous pregnancies[J]. J Obstet Gynaecol Res, 2025, 51: e16107. DOI: 10.1016/j.ajoggr.2023.100198.
    [17] LU Y, JING P, ZHAO H, et al. Efficacy and safety of double balloon catheter and dinoprostone for labor induction in multipara at term[J]. Arch Gynecol Obstet, 2023, 309: 1235-1243.
    [18] CANADAS J V, LOPEZ M, MARTINEZ M, et al. Intracervical double-balloon catheter versus dinoprostone for cervical ripening in labor induction in pregnancies with a high risk of uterine hyperstimulation[J]. Arch Gynecol Obstet, 2021, 304(6): 1475-1484. doi: 10.1007/s00404-021-06071-1
    [19] TAKAKURA S, TANAKA H, ENOMOTO N, et al. The successful use of nitroglycerin for uterine hyperstimulation with fetal heart rate abnormality caused by a controlled-release dinoprostone vaginal delivery system (propess): a case report[J]. Medicina (Kaunas), 2021, 57(5): 478-478. doi: 10.3390/medicina57050478
    [20] YANG C, QIAN L L, ZHANG Y, et al. Comparison of the efficacy and safety of dinoprostone and double-balloon catheters in cervical ripening: a propensity score matching retrospective study[J]. Ginekol Pol, 2024, 96: 161-167.
    [21] ALICIA R, RODRIGUEZ Z, SANTAMARIÑA E, et al. Effectiveness and safety of the double intracervical balloon vs dinoprostone in patients with previous cesarean section[J]. Reprod Sci, 2024, 31: 3148-3158. doi: 10.1007/s43032-024-01617-5
表(2)
计量
  • 文章访问数:  8
  • HTML全文浏览量:  5
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2025-08-27
  • 网络出版日期:  2026-10-23

目录

    /

    返回文章
    返回